Goldman Sachs Group Inc. Sells 34,963 Shares of Lineage Cell Therapeutics, Inc. $LCTX

Goldman Sachs Group Inc. trimmed its holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 9.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 350,103 shares of the company’s stock after selling 34,963 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.15% of Lineage Cell Therapeutics worth $158,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Two Sigma Advisers LP boosted its stake in Lineage Cell Therapeutics by 312.2% in the 4th quarter. Two Sigma Advisers LP now owns 86,964 shares of the company’s stock worth $44,000 after purchasing an additional 65,864 shares during the period. Squarepoint Ops LLC bought a new position in shares of Lineage Cell Therapeutics during the 4th quarter worth $46,000. ORG Partners LLC bought a new stake in Lineage Cell Therapeutics during the first quarter valued at about $47,000. Deutsche Bank AG increased its holdings in shares of Lineage Cell Therapeutics by 196.0% during the fourth quarter. Deutsche Bank AG now owns 174,702 shares of the company’s stock valued at $87,000 after acquiring an additional 115,672 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Lineage Cell Therapeutics by 9.9% during the first quarter. Rhumbline Advisers now owns 201,447 shares of the company’s stock valued at $91,000 after acquiring an additional 18,092 shares in the last quarter. 62.47% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. D. Boral Capital reiterated a “buy” rating and set a $2.00 price target on shares of Lineage Cell Therapeutics in a research report on Wednesday, August 27th. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research note on Monday, June 23rd. Four research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $4.25.

Lineage Cell Therapeutics Price Performance

NYSEAMERICAN LCTX opened at $1.79 on Tuesday. Lineage Cell Therapeutics, Inc. has a 1-year low of $0.37 and a 1-year high of $1.80. The company has a market capitalization of $408.76 million, a P/E ratio of -9.94 and a beta of 1.66. The business has a 50 day moving average price of $1.23 and a 200 day moving average price of $0.85.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.